Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2024-04-24 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于续聘公司2024年度审计机构的公告
Regulatory Filings Classification · 90% confidence The document is an announcement regarding the reappointment of the company's audit firm for the fiscal year 2024. It details the audit firm's background, qualifications, and the approval process by the board and supervisory committee. There is no actual audit report or financial statements included, only information about the audit firm and the decision to reappoint it. The document length is 2891 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR) because it relates to audit matters but is not the audit report itself. However, given the short length and nature as an announcement of audit firm reappointment, it aligns more closely with Regulatory Filings (RNS) as it does not contain the audit report or detailed audit results but is a regulatory disclosure about audit firm appointment.
2024-04-24 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 15th meeting of the 5th Board of Directors of 福安药业 (Fuan Pharmaceutical Group Co., Ltd.) held on April 24, 2024. It includes approvals of various reports and proposals related to the 2023 fiscal year, such as the General Manager's work report, Board work report, financial statements, audit report, internal control evaluation, profit distribution plan, appointment of auditors, accounting policy changes, and the 2024 Q1 report. The document also mentions that these reports are published simultaneously on the China Securities Regulatory Commission designated disclosure website. The document is a formal announcement of board meeting resolutions and does not contain the full reports themselves but references them and states they are published elsewhere. The document is over 5,000 characters and contains substantive content about board decisions but is not the full annual report or audit report itself. It is not a simple notice of report publication but a board meeting resolution announcement. This fits best with the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board, including approval of reports and plans to be submitted to the shareholders' meeting. Therefore, the classification is MANG with high confidence.
2024-04-24 Chinese
关于为子公司申请银行授信融资提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 福安药业（集团）股份有限公司 regarding providing guarantees for bank credit financing for its subsidiaries. It details the credit limits, banks involved, guarantee parties, and financial data of the subsidiaries. The document includes board and supervisory opinions and references board meeting resolutions approving the guarantees. There is no indication that this is a full financial report, audit report, or earnings release. It is a specific announcement about financing guarantees and related credit arrangements, which fits the category of Capital/Financing Update (CAP). The document length is 3397 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2024-04-24 Chinese
关于2023年度利润分配预案的公告
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from the company 福安药业 regarding the 2023年度利润分配预案 (2023 annual profit distribution plan). It details the proposed dividend payout per share, the legal compliance of the plan, and the approvals by the board and supervisory committee. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution proposal and related approvals. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders. The document length is short (1628 characters), and it is not a full annual report or earnings release but a specific dividend announcement.
2024-04-24 Chinese
董事会审计委员会对会计师事务所2023年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee evaluating the performance of the accounting firm for the 2023 fiscal year. It discusses the audit firm's qualifications, the audit process, communication with management, and the issuance of the audit report for the 2023 annual financial statements. The document references the audit of the 2023 annual financial report and the committee's supervision of the audit process. It is not the audit report itself but a supervisory and evaluative report by the audit committee on the auditor's performance and the audit process. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal or regulatory oversight related to audits, excluding full annual reports. The document length is 2385 characters, which is short but contains substantive content about the audit process and evaluation, not merely an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2023
2024-04-24 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed by the Supervisory Board of 福安药业（集团）股份有限公司 during their 13th meeting of the 5th Supervisory Board. It includes approvals of various reports and proposals related to the 2023 fiscal year, such as the 2023 Supervisory Board Work Report, 2023 Financial Statements, 2023 Audit Report, 2023 Annual Report, Internal Control Evaluation Report, Profit Distribution Plan, Accounting Policy Changes, and the 2024 First Quarter Report. The document also mentions that these reports are published simultaneously on the official disclosure website and that these resolutions will be submitted to the 2023 Annual General Meeting for approval. The document itself is not the full annual report or audit report but an official announcement of the Supervisory Board's review and approval of these reports and proposals. The length is 3545 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official regulatory announcement of supervisory board resolutions and report approvals, not the reports themselves.
2024-04-24 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.